osimertinib联合铂类与etoposide用于EGFR/TP53/RB1突变转移性肺癌组织学转化高风险患者
Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation
Science Translational Medicine 2026年第18卷第875期发表研究,考察osimertinib联合铂类与etoposide用于存在组织学转化风险的转移性EGFR/TP53/RB1突变肺癌患者。目前仅见摘要信息,原文摘要未提供样本量、主要终点与效应量等具体结果。
原文摘要
出版方登记 · CrossrefAlthough EGFR inhibitors are highly effective for treating EGFR- mutant lung adenocarcinomas ( EGFR + LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR + LUAD at high risk of transformation ( TP53 / RB1 -deficient) and treated them with first-line osimertinib combined with platinum and etoposide. Despite the addition of SCLC-directed chemotherapy, nearly half of patients (5 of 11) underwent SCLC transformation, with median progression-free survival of 11 months and overall survival of 33 months. Genomic and single-cell transcriptomic profiling of patient samples revealed clinical and subclinical plasticity associated with TP53 / RB1 comutations, including histological transformation to SCLC, as well as mesenchymal and squamous histologies. These changes in plasticity were linked to progressive disruption of the RB pathway, leading to altered chromatin accessibility and induction of neuronal differentiation and epithelial-to-mesenchymal transition transcriptional programs, further intensified by osimertinib treatment. These findings provide insights into the role of plasticity in mediating drug tolerance.
页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文
来源:Science Translational Medicine · science.org